Immunotherapy restores therapeutic efficacy of fecal microbiome transplants to treat Clostridioides difficile

Abstract

Microbiome-based therapeutics to treat enteric bacterial infections requires stable engraftment of transplanted beneficial bacteria that target and eliminate the pathogen. The host factors that determine whether a microbiome transplant engrafts remain largely unresolved. Here we demonstrate that Interleukin-10 (IL-10) signaling deficiency leads to impaired fecal microbiota transplantation (FMT) engraftment and failure to resolve Clostridioides difficile infection in mice. In the absence of IL-10-mediated immunoregulation provided by Foxp3+ Treg cells, increased IFN-{gamma} signaling in the intestine leads to elevated production of reactive oxygen/nitrogen species (ROS/RNS) by neutrophils and epithelial cells that supports the growth of inflammation-tolerant microbes, inhibits FMT engraftment, and impairs resolution of C. difficile. FMT treatment success can be restored by antibody-mediated blockade of IFN-{gamma} signaling, neutrophil depletion or inhibition of ROS/RNS production. Lastly, we developed an Il10-mRNA-LNP immunotherapy to boost IL-10 signaling in FMT Non-Responsive mice and demonstrate that Il10-mRNA-LNP administration is sufficient to restore FMT engraftment and subsequent resolution of C. difficile. Combined, these data support a mechanism by which IL-10 released by Treg cells limits IFN-{gamma} mediated intestinal inflammation thereby promoting an intestinal microenvironment receptive to FMT engraftment and resolution of C. difficile. These data demonstrate that the host's immune status can be therapeutically modulated to improve microbiome-based approaches to treat infection.

In silico assessment of barnyard millet and blue pea derived bioactive peptides against Salmonella enterica Serovar Typhi and Clostridioides difficile
Srujal Kacha, Romita Guchhait, Avani Panickar +2
Scientific Reports27 Oct 2026Peer-reviewedCC BY-NC-ND 4.0Full textMicrobiologyCrossref
Metabolic network restoration, not donor microbial engraftment, associates with resolution of recurrent Clostridioides difficile infection
Brendan T. Whitman, Ramin Karimianghadim, Benjamin Auch +4
iScience16 Oct 2026Peer-reviewedCC BY-NC-ND 4.0Full textMicrobiologyCell PressPMCCrossrefEurope PMC
Receptor-binding domain 2 of Clostridioides difficile binary toxin as a promising vaccine component against C. difficile infection
S. Wang, J. S. Heuler, Y. Nakanishi +2
bioRxiv30 Aug 2026PreprintCC BYFull textMicrobiologybioRxiv
The Microbiota Dictates Vendor-Derived Differences in a Murine Clostridioides difficile Infection Model
L. Keogh, L. Dridi, B. Thurairajah +4
bioRxiv31 Aug 2026PreprintCC BY-NC-NDFull textMicrobiologybioRxiv
An endolysin-expressing probiotic attenuates Clostridioides difficile infection in germ-free and dysbiotic microbiota-associated mice
A. Cheemadan, P. Harnvoravongchai, S. More +2
bioRxiv7 Oct 2026PreprintCC BY-NC-NDFull textMicrobiologybioRxiv

Cite

BibTeX RIS

BibTeX

@misc{mridha2026immunotherapy,
  title = {{Immunotherapy restores therapeutic efficacy of fecal microbiome transplants to treat Clostridioides difficile}},
  author = {S. Mridha and M. Z. Alam and J. E. Denny and E. N. Hulit and M. Tran Ha and K. S. Mears and D. D. Brown and M.-G. Alameh and M. C. Abt},
  howpublished = {bioRxiv},
  year = {2026},
  month = sep,
  doi = {10.64898/2026.09.17.752434},
  url = {https://www.biorxiv.org/content/10.64898/2026.09.17.752434v1},
  note = {CC BY-NC-ND},
}

RIS

TY  - UNPB
TI  - Immunotherapy restores therapeutic efficacy of fecal microbiome transplants to treat Clostridioides difficile
AU  - S. Mridha
AU  - M. Z. Alam
AU  - J. E. Denny
AU  - E. N. Hulit
AU  - M. Tran Ha
AU  - K. S. Mears
AU  - D. D. Brown
AU  - M.-G. Alameh
AU  - M. C. Abt
PY  - 2026
DA  - 2026/09/17
PB  - bioRxiv
DO  - 10.64898/2026.09.17.752434
UR  - https://www.biorxiv.org/content/10.64898/2026.09.17.752434v1
AB  - Microbiome-based therapeutics to treat enteric bacterial infections requires stable engraftment of transplanted beneficial bacteria that target and eliminate the pathogen. The host factors that determine whether a microbiome transplant engrafts remain largely unresolved. Here we demonstrate that Interleukin-10 (IL-10) signaling deficiency leads to impaired fecal microbiota transplantation (FMT) engraftment and failure to resolve Clostridioides difficile infection in mice. In the absence of IL-10-mediated immunoregulation provided by Foxp3+ Treg cells, increased IFN-{gamma} signaling in the intestine leads to elevated production of reactive oxygen/nitrogen species (ROS/RNS) by neutrophils and epithelial cells that supports the growth of inflammation-tolerant microbes, inhibits FMT engraftment, and impairs resolution of C. difficile. FMT treatment success can be restored by antibody-mediated blockade of IFN-{gamma} signaling, neutrophil depletion or inhibition of ROS/RNS production. Lastly, we developed an Il10-mRNA-LNP immunotherapy to boost IL-10 signaling in FMT Non-Responsive mice and demonstrate that Il10-mRNA-LNP administration is sufficient to restore FMT engraftment and subsequent resolution of C. difficile. Combined, these data support a mechanism by which IL-10 released by Treg cells limits IFN-{gamma} mediated intestinal inflammation thereby promoting an intestinal microenvironment receptive to FMT engraftment and resolution of C. difficile. These data demonstrate that the host's immune status can be therapeutically modulated to improve microbiome-based approaches to treat infection.
ER  -

Abstract

Related

Cite